NACP, the precursor of non-A component of Alzheimer's disease (AD) amyloid (alpha-synuclein) is a synaptic molecule that accumulates in AD plaques. Recent studies have shown that a mutation in NACP is associated with familial Parkinson disease and that Lewy bodies are immunoreactive with antibodies against this molecule. In this context, the central hypothesis of this project is that abnormal accumulation/compartmentalization of NACP is involved in the process of neurodegeneration in Lewy body disease (LBD). The main objective of this proposal is to better understand the mechanisms through which abnormal accumulation of NACP leads to neurodegeneration. For this purpose, we propose the following Specific Aims: 1) To determine the relationship between abnormal NACP/alpha- synuclein accumulation and neurodegeneration in the brains of patients with LBD. We hypothesize that in LBD abnormal accumulation of NACP/alpha- synuclein will result in neurodegeneration of cells within the mesolimbic, mesocortical and striatonigral systems. For this purpose, we propose to determine the relationship between NACP/alpha-synuclein levels in synapses, neurons and neurites and cell counts, synapse density and apoptosis in postmortem brains (frontal, temporal, hippocampus, basal ganglial, cingulate and mesencephalon) from patients with LBD. 2) To develop in vivo models to investigate mechanisms which NACP/alpha- synuclein promotes neurodegeneration. We hypothesize that abnormal NACP/alpha-synuclein accumulation resulting over-expression of NACP/alpha-synuclein will result in synaptic damage and neuronal cell death in transgenic (tg) mice. Furthermore, we postulate that mutant NACP/alpha-synuclein might accelerate this process. For this purpose we propose to investigate the patterns of neurodegeneration in the brains of young and old tg mice over-expressing mutant and wildtype human NACP/alpha-synuclein under the control of the platelet-derived growth factor (PDGF) promoter. 3) To determine if risk factors associated with AD increase susceptibility to NACP/alpha-synuclein-induced neurodegeneration in tg mice. We hypothesize that known genetic risk factors for AD such as the presence of apolipoprotein E4 allele (ApoEepsilon4) and amyloid precursor protein (APP) mutations will enhance NACP/alpha-synuclein tg mice will be crossbred with apoE-deficient (knockout), ApoEepsilon3 or E4 tg mice, and with amyloid precursor protein (APP) wildtype and mutant tg MICE. Taken together these studies will help to better delineate the molecular and cellular mechanisms involved in neurodegeneration in LBD. The models and paradigms developed will also help to identify potential targets that will prevent neuronal cell injury in neurodegenerative disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
3P50AG005131-16S3
Application #
6395447
Study Section
Project Start
1999-08-15
Project End
2000-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
16
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71
Blue, Elizabeth E; Bis, Joshua C; Dorschner, Michael O et al. (2018) Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project. Dement Geriatr Cogn Disord 45:1-17
Gallagher, Damien; Kiss, Alex; Lanctot, Krista L et al. (2018) Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors. J Clin Psychiatry 80:
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Golde, Todd E; DeKosky, Steven T; Galasko, Douglas (2018) Alzheimer's disease: The right drug, the right time. Science 362:1250-1251
Young, Jessica E; Fong, Lauren K; Frankowski, Harald et al. (2018) Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer's Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein. Stem Cell Reports 10:1046-1058
Reas, Emilie T; Hagler Jr, Donald J; White, Nathan S et al. (2018) Microstructural brain changes track cognitive decline in mild cognitive impairment. Neuroimage Clin 20:883-891
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Graves, Lisa V; Holden, Heather M; Van Etten, Emily J et al. (2018) New Yes/No Recognition Memory Analysis on the California Verbal Learning Test-3: Clinical Utility in Alzheimer's and Huntington's Disease. J Int Neuropsychol Soc 24:833-841
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307

Showing the most recent 10 out of 914 publications